Journal of Clinical PracticeJournal of Clinical PracticeКлиническая практика2220-30952618-8627Eco-Vector830210.17816/clinpract5371-82ArticlesСтатьиReview ArticleCLASSIFICATION, DIAGNOSIS, AND APPROACH TO TREATMENT FOR ANGIOEDEMAАНГИООТЕКИ: КЛАССИФИКАЦИЯ, ДИАГНОСТИКА, ПОДХОДЫ К ТЕРАПИИBorisovaT VБорисоваТатьяна Вадимовна

врач отделения аллергологии и иммунологии ФГБУ ФНКЦ ФМБА России

SokurenkoS IСокуренкоСергей Иванович

зав. отделением аллергологии и иммунологии ФГБУ ФНКЦ ФМБА России, д.м.н., профессор

ФГБУ ФНКЦ ФМБА России1509201453NO3 (2014)№3 (2014)718216032018Copyright ©; 2014, Borisova T.V., Sokurenko S.I.Copyright ©; 2014, Борисова Т.В., Сокуренко С.И.2014Borisova T.V., Sokurenko S.I.Борисова Т.В., Сокуренко С.И.https://creativecommons.org/licenses/by-nc-nd/4.0https://clinpractice.ru/clinpractice/article/view/8302

Angioedema is defined as localized and self-limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability caused by the release of vasoactive mediators. When angioedema recurs without significant wheals, the patient should be diagnosed to have angioedema as distinct disease. In the absence of the accepted classification, different types of angioedema are not uniquely identified. Four types of accuired and three types of hereditary angioedema were identified as separate forms from the analysis of literature. Here, we summarize the data and the resulting classification and treatment of angioedema.

Ангиоотек - это локализованный и самоизолированный отек подкожной и подслизистой локализации, вызванный временным повышением проницаемости капилляров из-за увеличения содержания вазоактивных медиаторов. Ангиоотек, протекающий без явлений крапивницы, должен рассматриваться как самостоятельное заболевание. В связи с отсутствием общепринятой классификации, диагностика представляет сложности. В настоящее время выделяют 4 вида приобретенного и 3 вида наследственного ангиоотека. В данном обзоре представлены обобщенные данные по классификации и лечению ангиоотеков.

angioedemaclinical immunologydermatologyurticariaангиоотекклиническая иммунологиядерматологиякрапивницаCicardi M., Aberer W., Banerji A., et al. Classification, diagnosis, and approach to treatment for angioedema; consensus report from the Heriditary Angioedema International Workgroup. Allergy 2014; 69: 602-16.Cicardi M, Banerji A, Bracho F, Malbran A, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-41.Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-57.Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M. Different rates of autoreactivity in patients with recurrent idiopathic angioedema associated or not with wheals. J Investig Allergol Clin Immunol 2012; 22: 87-91.Farkas H. Current pharmacotherapy of bradykinin- mediated angioedema. Expert Opin Pharmacother 2013;14: 571-86.Rye Rasmussen EH, Bindslev-Jensen C, Bygum A. Angioedema-assessment and treatment. Tidsskr Nor Laegeforen 2012; 132: 2391-5.Du-Thanh A, Raison-Peyron N, Drouet C, Guillot B. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema. Allergy 2010;65:793-5.Colas C, Montoiro R, Fraj J, Garces M, Cubero JL, Caballero T. Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J Investig Allergol Clin Immunol 2012; 22: 520-21. Клиническая практика №3, 2014 http://clinpractice.ru 77 ОбзорыDel Corso I, Puxeddu I, Sardano E, Geraci S, Breggia M, Rocchi V, et al. Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant. Ann Allergy Asthma Immunol 2012;108:460-61.Montinaro V, Loizzo G, Zito A, Castellano G, Gesualdo L. Successful treatment of a facial attack of angioedema with icatibant in a patient with idiopathic angioedema. Am J Emerg Med 2013;31:1295.Sanchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012; 5:125-47.La Corte AL, Carter AM, Rice GI, Duan QL, Rouleau GA, Adam A, et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat 2011;32:1326-31.Toh S, Reichman ME, Houstoun M, Ross Southworth M, Ding X, Hernandez AF, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582-89.Makani H, Messerli FH, Romero J, Wever- Pinzon O, Korniyenko A, Berrios RS, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012;110: 383-91.Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol 2013;13: 337-44.Benson BC, Smith C, Laczek JT. Angiotensin converting enzyme inhibitor-induced gastrointestinal angioedema: a case series and literature review. J Clin Gastroenterol 2013; 47: 844-9.Beltrami L, Zanichelli A, Zingale L, Vacchini R, Carugo S, Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29: 2273-7.Branellec A, Bouillet L, Javaud N, Mekinian A, Boccon-Gibod I, Blanchard-Delaunay C, et al. Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol 2012; 32: 936-41.Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F, et al. A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol 2013;131:1491-3.Hassan A, Amarger S, Tridon A, Ponard D, Souteyrand P, D'Incan M. Acquired angioedema responding to rituximab. Acta Derm Venereol 2011;91:733-4.Lam D, Levy N, Nickerson J, Gruenberg D, Lansigan F. Acquired angioedema and marginal zone lymphoma. J Clin Oncol 2012;16:e551-e553.Bygum A, Broesby-Olsen S. Rapid resolution of erythema marginatum after icatibant in acquired angioedema. Acta Derm Venereol 2011;91:185-186.Weller K, Magerl M, Maurer M. Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol 2011; 25: 119-20.Zanichelli A, Bova M, Coerezza A, Petraroli A, Triggiani M, Cicardi M. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 2012; 67: 1074-7.Patel NS, Fung SM, Zanichelli A, Cicardi M, Cohn JR. Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. Allergy Asthma Proc 2013; 34: 72-7.Longhurst H, Cicardi M. Hereditary angiooedema. Lancet 2012; 379: 474-81.Lopez-Lera A, Favier B, de la Cruz RM, Garrido S, et al. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol 2010;126:1307-10.Bafunno V, Divella C, Sessa F, Tiscia GL, Castellano G, Gesualdo L et al. De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedema. J Allergy Clin Immunol 2013;132:748-750.Lopez-Lera A, Garrido S, Roche O, Lopez-Trascasa M. SERPING1 mutations in 59 families with hereditary angioedema. Mol Immunol 2011;49:18-27.Thelwel C, Rigsby P, Longstaff C, ISTH-SSC Subcommittee on Factor XI and Contact System. An international collaborative study to establish the WHO 1st international standards for C1-inhibitor, plasma and concentrate. J Thromb Haemost 2011;9:2097-2099.Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308-20.Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012;5:182-199.Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011;66:192-6.Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:58-64.Farkas H, Zotter Z, Csuka D, Szabo E, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor - a long-term survey. Allergy 2012;67:1586-93.Grant JA, White MV, Lee HH, Fitts D, Kalfus IN, Uknis ME et al. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc 2012;33:348-53.Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011;141:31-35.Kiss N, Barabas E, Varnai K, Halasz A, Varga LA, Prohaszka Z et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 2013;149:142-5.Marcos C, Lopez Lera A, Varela S, Linares T, Alvarez-Eire MG, Lopez-Trascasa M. Clinical, biochemical, and genetic characterization of type III hereditary angioedema in 13 Northwest Spanish families. Ann Allergy Asthma Immunol 2012;109:195-200.